Compliance with follow-up in patients with testicular cancer receiving adjuvant chemotherapy: A novel study

Résumé

Abstract Purpose The aim of this study was to investigate the compliance with follow-up in patients receiving adjuvant chemotherapy (ACT) for testicular cancer at two academic hospitals. Methods. The study analyzed 104 patients with testicular tumors who had undergone surgery at least a year before and received ACT between March 2017 to March 2022. The mean follow-up was 29.2 ± 16.2 (12–73) months. Patients were classified as fully compliant (100% compliance), moderately compliant (50–99%), poorly compliant (1–49%), and non-compliant (no attendance) according to their compliance with the follow-up schedule. Results At the end of the first year, 76% of patients were fully compliant. By the end of the second year, this number dropped to 50%. Furthermore, 25% of patients were identified as non-compliant in the second year, and only 4.3% in the third year. When comparing patients who were compliant and non-compliant at first and second-year follow-up, no statistically significant difference was found according to age, tumor size, disease stage, or ACT regimen (p = 0.938, p = 0.784, p = 0.867, and p = 0.282, respectively). Conclusion and Implications for Cancer Survivors This study showed that full compliance with follow-up gradually decreased over the years and that the factors examined were not able to predict this decrease. Prospective studies can help to design individualized education and follow-up programs, taking into account the tumor stage of each patient.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0